TY  - GEN
AU  - Bendell,Johanna C
AU  - Bischoff,Helge G
AU  - Hwang,Jimmy
AU  - Reinhardt,Hans Christian
AU  - Zander,Thomas
AU  - Wang,Xuejing
AU  - Hynes,Scott
AU  - Pitou,Celine
AU  - Campbell,Robert
AU  - Iversen,Philip
AU  - Farrington,Daphne L
AU  - Bell-McGuinn,Katherine
AU  - Thomas,Michael
TI  - A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer
SN  - 1573-0646
PY  - 2021///0909
KW  - Adult
KW  - Aged
KW  - Antineoplastic Agents
KW  - administration & dosage
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Checkpoint Kinase 1
KW  - antagonists & inhibitors
KW  - Female
KW  - Humans
KW  - Imidazoles
KW  - Male
KW  - Middle Aged
KW  - Models, Biological
KW  - Neoplasms
KW  - drug therapy
KW  - Protein Kinase Inhibitors
KW  - Pyrazines
KW  - Pyrazoles
KW  - Pyridines
KW  - Treatment Outcome
KW  - p38 Mitogen-Activated Protein Kinases
N1  - Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1007/s10637-019-00873-6
ER  -